bioMerieux

Activities: Regulatory Analysis

Trending Articles

  1. NICE approves KEYTRUDA as first perioperative immunotherapy for locally advanced head and neck cancer MSD's KEYTRUDA (pembrolizumab) has received NICE approval as a neoadjuvant and adjuvant therapy for resectable LA HNSCC—the first immunotherapy recommended in this...
  2. Destination Russia for new NYK Logistics warehouse Logistics specialist NYK is expanding its market presence with the launch of new warehousing operation in Moscow, Russia.
  3. Pfizer agrees sale of consumer healthcare business to J&J Pfizer Inc has reached an agreement to sell its consumer healthcare business to Johnson & Johnson (J&J) for US$16.6bn (euro13.2bn) in cash.
  4. Pfizer's HYMPAVZI receives positive CHMP opinion for haemophilia A and B patients with inhibitors The EMA's Committee for Medicinal Products for Human Use has recommended expanding the approved indication for Pfizer's HYMPAVZI to include adolescents and adults with...
  5. AstraZeneca's tozorakimab meets primary endpoint in both Phase III COPD trials AstraZeneca has reported positive results from the OBERON and TITANIA Phase III trials, with tozorakimab significantly reducing moderate-to-severe COPD exacerbations compared...

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

Related Content

Regulatory

bioMérieux and JMI Laboratories partner to fight antimicrobial resistance

JMI Laboratories is a recent member of the Element Group, a leading global Testing, Inspection and Certification (TIC) company, through acquisition in November 2021
Drug Delivery

InDevR raises $9m in series B financing

ioMérieux will also become the exclusive distributor of the VaxArray portfolio in Europe
Regulatory

bioMérieux receives FDA clearance for mass spectrometry ID system

With 1.3 million deaths worldwide annually, antimicrobial resistance (AMR) is a global health priority
Manufacturing

Recombinant Factor C assay to aid demand for LAL endotoxin testing

Kevin Williams from bioMerieux discusses the recombinant Factor C assay that has been developed to help alleviate the pressures of a growing demand for the Limulus amoebocyte lysate assay
Analysis

bioMérieux launches automated diagnostic solution for microbial detection

EviSight Compact provides reliable results for increased product safety and reduces costs for pharmaceutical companies
Finance

BioMérieux acquires Hyglos for a total consideration of €24m

Expands its offering for the detection of endotoxins in pharmaceutical products
Analysis

Revolutionised and Robust: Environmental Identification Webinar - mid-October

Environmental identification, including moulds, by MALDI-TOF Mass Spectrometry
Subscribe now